|Dosage Form||Solution for injection in pre-filled syringe|
|Strength per Unit||250 mg/5 ml|
|Drug Class||Endocrine therapy|
|Indication||Fulvestrant EVER Pharma in indicated:|
as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic
breast cancer in postmenopausal women:
– not previously treated with endocrine therapy, or
– with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on
in combination with palbociclib for the treatment of hormone receptor (HR)-positive, human
epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast
cancer in women who have received prior endocrine therapy (see section 5.1).
In pre- or perimenopausal women, the combination treatment with palbociclib should be
combined with a luteinizing hormone releasing hormone (LHRH) agonist.
Fulvestrant EVER Pharma is a prescription medication. Information for healthcare professionals only.
See the Summary of Product Characteristics for full information about the medication.